Pierre Pujol

Pierre Pujol has extensive work experience in various leadership roles. Pierre is currently working as the Chief Business Officer at Trilo Therapeutics since January 2022. Prior to this, they co-founded and served as a Senior Consultant at Airlib Inc, where they developed an IOT solution for real-time traffic pollution mapping. Pierre was also a mentor at Nasdaq Entrepreneurial Center from July 2020 to February 2022.

Pierre's previous experience includes serving as the Chief Executive Officer at Oakbio Inc. (now NovoNutrients Inc.), where they focused on developing a bioprocess for industrial emissions capture and conversion. Pierre managed grants and collaborations with notable organizations such as Shell Petroleum and Lafarge SA. Before that, they worked as a Senior Consultant at PartnerVision Ventures, a hi-tech incubator.

Additionally, Pierre held the position of VP, Corporate Business Development at MAXYGEN, where they led strategic planning, portfolio review, and M&A activities. Pierre also served as the Head of the Global Portfolio Analysis Group at Glaxo Welcome Plc. (now GSK), where they designed the "Go/No-Go" product review process and co-chaired the review of several products. Earlier in their career, they served as the Director of Strategic Planning and Business Development at CHIRON Corp., where they led the development of the company's first-ever strategic plan and performed valuation studies for patents and products.

Overall, Pierre Pujol has a strong background in business development, strategic planning, and leadership roles across various industries.

Pierre Pujol has a diverse education history. Pierre holds an MBA from INSEAD, where they were additionally admitted to the Harvard MBA program. Pierre also has a degree from AgroParisTech, where they earned an MSc & Engineering, and completed three years towards a PhD in Macroeconomics. Additionally, they obtained a BSc (DEUG) in Biology from Université Paul Sabatier Toulouse III.